Geode Capital Management LLC boosted its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 2.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,837,985 shares of the biotechnology company's stock after buying an additional 127,708 shares during the quarter. Geode Capital Management LLC owned approximately 2.34% of BioCryst Pharmaceuticals worth $36,776,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Deerfield Management Company L.P. Series C lifted its position in shares of BioCryst Pharmaceuticals by 62.9% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company's stock worth $50,279,000 after buying an additional 3,140,804 shares during the last quarter. Fisher Asset Management LLC raised its stake in BioCryst Pharmaceuticals by 16.9% during the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company's stock worth $25,369,000 after acquiring an additional 481,359 shares in the last quarter. Two Sigma Advisers LP lifted its position in BioCryst Pharmaceuticals by 13.6% in the third quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company's stock valued at $16,576,000 after acquiring an additional 261,500 shares during the last quarter. Rice Hall James & Associates LLC boosted its stake in BioCryst Pharmaceuticals by 4.0% in the third quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company's stock valued at $16,444,000 after acquiring an additional 84,102 shares in the last quarter. Finally, FMR LLC grew its holdings in shares of BioCryst Pharmaceuticals by 2.4% during the third quarter. FMR LLC now owns 1,988,389 shares of the biotechnology company's stock worth $15,112,000 after purchasing an additional 46,110 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on BCRX. Needham & Company LLC reiterated a "buy" rating and set a $14.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Finally, Barclays increased their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an "equal weight" rating in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $15.60.
Check Out Our Latest Research Report on BCRX
BioCryst Pharmaceuticals Stock Down 1.4 %
BCRX stock traded down $0.11 during trading on Wednesday, hitting $7.67. The company had a trading volume of 753,880 shares, compared to its average volume of 2,837,639. The firm has a 50-day moving average price of $7.64 and a 200-day moving average price of $7.45. The firm has a market cap of $1.59 billion, a PE ratio of -12.57 and a beta of 1.79. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $8.88.
BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The company had revenue of $117.10 million during the quarter, compared to analysts' expectations of $113.99 million. During the same quarter last year, the business posted ($0.19) earnings per share. The company's revenue for the quarter was up 35.1% compared to the same quarter last year. Sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.
BioCryst Pharmaceuticals Profile
(
Free Report)
BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
Further Reading
Before you consider BioCryst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.
While BioCryst Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
